|
|
|
11-50 employees
View all
|
|
Medical Devices
|
|
4 Rue du Dauphine, Vaulx-en-Velin, Auvergne-Rhône-Alpes 69120, FR
|
|
EDAP TMS is a high-tech medical company listed on the Nasdaq (EDAP) which develops, manufactures and markets minimally invasive medical devices using ultrasound technology for various medical applications and offers a wide portfolio of complementary distribution products in urology.
By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in 2013 in Europe and in 2018 in the US as the answer to all requirements for ideal prostate tissue ablation as a complement to the existing FDA-cleared Ablatherm® Robotic HIFU and Ablatherm® Fusion.
As a pioneer and key player in the field of extracorporeal shock wave lithotripsy (ESWL), EDAP TMS exclusively utilizes the latest generation of shock wave source in its Sonolith® range of ESWL systems.
EDAP TMS is listed on NASDAQ market in New York under ticker symbol “EDAP”.
|
Marc Oczachowski is the CEO of EDAP TMS. To contact Marc Oczachowski email at [email protected].
The decision makers in EDAP TMS are Damien Desmedt, Emmanuel Carre, Franck Lepoivre, etc. Click to Find EDAP TMS decision makers emails.
EDAP TMS specializes in developing minimally invasive medical devices that utilize advanced ultrasound technology. Their primary focus is on devices for urology, particularly in the treatment of prostate cancer through High-Intensity Focused Ultrasound (HIFU). Additionally, they offer solutions for the treatment of urinary stones using Extracorporeal Shock Wave Lithotripsy (ESWL).
HIFU is a non-invasive treatment option that uses focused ultrasound waves to heat and destroy cancerous tissue in the prostate. The procedure is performed under ultrasound guidance, allowing for precise targeting of the tumor while minimizing damage to surrounding healthy tissue. This method offers patients a quicker recovery time and fewer side effects compared to traditional surgical options.
EDAP TMS primarily serves the healthcare industry, focusing on urology and oncology. Their innovative medical devices are used in hospitals, outpatient clinics, and specialized treatment centers. The company is also involved in research and development to advance therapeutic ultrasound applications, contributing to the broader medical device industry.
Extracorporeal Shock Wave Lithotripsy (ESWL) is a non-invasive procedure that uses shock waves to break down kidney stones into smaller fragments, which can then be passed naturally through the urinary tract. The benefits of ESWL include reduced recovery time, minimal discomfort, and the avoidance of surgical intervention, making it a preferred choice for many patients with urinary stones.
Yes, EDAP TMS is committed to research and development to enhance their existing technologies and explore new applications of therapeutic ultrasound. The company collaborates with medical professionals and institutions to innovate and improve treatment options for patients, ensuring they remain at the forefront of the medical device industry.
Healthcare providers interested in EDAP TMS's products and services can visit their official website or contact their sales team directly. The company offers comprehensive support, including product demonstrations, training, and ongoing technical assistance to ensure that healthcare professionals can effectively utilize their advanced medical devices in clinical settings.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.